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Background. Because obesity may be a risk factor for prostate cancer, we investigated proliferative eﬀects of adipocytes-derived
hormone leptin on human prostate cancer cells and assessed the role of mitogen-activated protein kinase (MAPK) signaling
pathway in mediating these actions. Material and Methods. Three human prostate cancer cell lines were treated with increasing
doses of recombinant leptin. Cell growth was measured under serum-free conditions using a spectrophotometric assay. Further,
WesternblottingwasappliedtodetectthephosphorylationofanERK1/2,andaspeciﬁcinhibitorofMAPK(PD98059;40µM)was
used. Results. In both androgen-resistant cell lines DU145 and PC-3, cell growth was dose-dependently increased by leptin after
24 hrs and 48 hrs of incubation, whereas leptin’s proliferative eﬀects on androgen-sensitive cell line LNCaP was less pronounced.
Further, leptin caused dose-dependent ERK1/2 phosphorylation in both androgen-resistant cell lines, and pretreatment of these
cells with PD98059 inhibited these responses. Conclusions. Leptin may be a potential link between obesity and risk of progression
of prostate cancer. Thus, studies on leptin and obesity association to prostate cancer should diﬀerentiate patients according to
androgen sensitivity.
1.Introduction
Among other serious diseases, obesity is known to be associ-
ated with an increased risk for a number of diﬀerent cancers
such as breast cancer, esophageal cancer, colon cancer,
renal cell cancer, and pancreatic cancer [1, 2]. Studies using
body fat measurement and disease stratiﬁcation according to
prostate cancer (PCa) stage have found a strong association
between obesity and PCa [3–5]. In Western population with
high fat intake and prevalence of obesity, the incidence
of clinically signiﬁcant prostate cancer and disease-speciﬁc
mortality rates are increasing [3]. Meanwhile, increased
levels of endogenous hormones associated with overweight
and obesity, such as sex steroids, insulin, insulin-like growth
factor I, and leptin, have been described as potential mech-
anisms linking obesity to prostate cancer [1]. In particular,
the fat hormone leptin has been shown to be positively
associated with prostate cancer [6–9]. Recently, there has
been an increasing interest on the study of cellular and
molecularmechanism of cancerbyenergyrestriction models
[10]. For instance, Berrigan et al. and Mai et al. observed
that the relationship between energetic balance and cancer
development could be explained to a great extent by
caloric restriction, as mediated through leptin [11, 12]. The
discovery and isolation of the human obese-gene and its
protein product, leptin, have led to numerous subsequent
studies linking leptin to obesity. Leptin, a 16kDa, 167-
amino acid peptide, is released mainly by adipocytes, which
contributes to the concept of adipocyte and adipose tissue as
an endocrine cell and an endocrine organ, respectively. After
binding to its receptors in the hypothalamus, leptin induces
a complex response partly resulting in regulation of body
weight and energy expenditure [13, 14]. In humans, levels
of leptin in the blood seem to correlate directly with body2 Journal of Oncology
mass and may increase from levels of 1–3ng/mL in non-
obese subjects to as high as 100ng/mL in obese individuals
[15].
Several recent studies have indicated that leptin acts as a
mitogenic factor in a variety of cell types including vascular
endothelial and smooth muscle cells, as well as normal and
neoplastic colonic, ovarian, and breast cells [16, 17]. Leptin
receptors have been shown to exist on various cancer cells
[18, 19]. The leptin receptor, ObR, is a member of the
class I cytokine-receptor family. While the short isoforms
of the leptin receptor seem to mediate the transport and
degradation of leptin, the long isoform, ObRb, expressed
by the hypothalamus and many peripheral cells, is reported
to be responsible for most of the central and peripheral
actions of leptin [19]. Both short and long isoforms of the
leptin receptor have been found in prostate cell membranes
[18, 20]. These receptors have been shown to be functional
in terms of their ability to activate mitogenic signaling
pathways. However, the exact mechanism by which leptin
exerts proliferative eﬀects on cancer cells, including those
from the prostate, is not fully understood. There is emerging
evidence that chronic hyperleptinemia associated with obe-
sitymightconstituteariskfactorforprostatecancer[21].We
previously have shown that leptin in vitro is able to induce
mitogenic actions in a group of human prostate cancer cell
lines [22]. In the present study, we tested the hypothesis,
whether the proliferative eﬀect of leptin in prostate cancer
cells is linked to the stage of androgen-sensitivity in these
cells. For this purpose, we sought to evaluated any diﬀerence
in response to leptin in androgen-sensitive and insensitive
prostate cancer cell lines.
2.MaterialsandMethods
2.1. Reagents. Human recombinant leptin was purchased
from Sigma Inc. (St. Louis, MO). Blocking reagent for West-
ern blotting (skim milk), rainbow-colored protein molecular
weight markers, ECL Plus (Amersham Pharmacia Biotech,
Piscataway, NJ), phospho-p44/42 MAPK antibody (ERK1/2,
rabbit polyclonal IgG1; Cell Signaling Technology Inc., Bev-
erly,MA),andMEKinhibitorPD98059(CellSignalingTech-
nology Inc. Beverly, MA) were obtained from the sources
indicated.
2.2. Cell Cultures. One human androgen-sensitive human
prostate adenocarcinoma cell line (LNCaP) and two andro-
gen-resistant human prostate cancer cell lines (DU145
and PC-3) were used for these experiments (CLS Corp.,
Germany). PC-3 cells were cultured in Ham’s F12K medium
supplemented with 2mM L-glutamine adjusted to contain
1.5g/L sodium bicarbonate and 10% fetal bovine serum.
DU145 cells were cultured in Minimum essential medium
Eagle with 2mM L-glutamine and Earle’s BSS adjusted to
contain 1.5g/L sodium bicarbonate, 0.1mM nonessential
aminoacids,and1.0mMsodiumpyruvate,90%;fetalbovine
serum, 10%. LNCaP cells were cultured in RPMI 1640 media
(Invitrogen, USA) supplemented with 2mM L-glutamine
adjusted to contain 1.5g/L sodium bicarbonate, 4.5g/L
glucose, 10mM HEPES, 1.0mM sodium pyruvate, and 10%
fetal bovine serum. Passages were carried out with trypsin-
EDTA. All cell lines were grown at 37◦Ci na na t m o s p h e r eo f
95% O2/5% CO2.
2.3. Treatments. For all experimental procedures, cells were
transferred to serum-free medium 24 hours after seeding.
After a further 24 hours, leptin was added at various con-
centrations (5–100ng/mL) and for diﬀerent treatment times
(up to 48 hours). For Western blot studies, we used only
one uniform time point of 1 hour for leptin treatment (5–
100ng/mL). Control cells were treated with vehicle (PBS).
Where inhibitor was used, cells were pretreated for 3 hours
with PD98059 (40µM) prior to leptin addition.
2.4.MeasurementofCellProliferation. TheXTTcolorimetric
assay (Roche, Mannheim, Germany) was used to detect cell
proliferation after 24 and 48 hours of incubation in the pres-
ence of leptin or vehicle. Cells were plated in 96-well plates at
a concentration of 5 × 103 cells per well. At designated time
points, XTT, a tetrazolium salt, was added to the each well
at a ﬁnal concentration of 0.3mg/mL. Plates were incubated
in the presence of XTT dye for 4h to allow for the formation
of the orange formazan dye product by metabolically active
cells. Absorbance was read spectrophotometrically at 450nm
using an ELISA plate reader. The data are reported as a
percentage of the untreated control. Assays were performed
at least ﬁve times and samples were run in triplicate.
2.5. Immunoblotting. Approximately 106 cells were plated
into each well of 6-well plates for these studies and treated
withleptinforvarioustimes.Allincubationswerestoppedby
washing (×3) with ice-cold phosphate-buﬀered saline (PBS).
Ice-cold lysis buﬀer was added (consisting of 1% Triton-X-
100, 1mM NaVO4,1µg/mL leupeptin, 1mg/mL pepstatin,
1mg/mL antipain, 1mM NaF, 1mM EDTA, and 100mg/mL
PMSF in PBS), and the cells were incubated at 4◦Cf o r
30 minutes. Cells were then scraped into microcentrifuge
tubes, centrifuged at 10,000rpm for 10 minutes, and the
supernatant retained. Aliquots of each sample were assayed
to determine protein content, and samples were adjusted
so that they contained equal amounts of protein. Samples
were then mixed with gel loading buﬀer (50mM Tris, pH
6.8, 2% SDS, 100mM DTT, 0.2% bromphenol blue, 20%
glycerol).Thesampleswereboiledfor5minutesandproteins
separated by SDS-PAGE. Separated proteins were transferred
onto a PVDF membrane (DuPont NEN, Boston, MA). The
membrane was washed in 1% blocking buﬀer for 30min,
followed by incubation with an appropriate dilution of
primary antibody against pERK1/2 or pAkt in blocking
buﬀer for 60 minutes. This was followed by washing (×3)
in Tris-buﬀered saline with 1% Tween (TBST). Following
washes, an HRP-conjugated secondary antibody was added
to the membrane in 1% blocking buﬀer and allowed to
incubate for an additional 30 minutes. This was followed
by further washing (×3) in TBST. Immunoreactive proteins
were detected using an enhanced chemiluminescence detec-
tion kit (ECL, Amersham Biosciences, Piscataway, NJ) and
exposure of the membrane to X-ray ﬁlm. Quantiﬁcation ofJournal of Oncology 3
protein phosphorylation was determined by densitometry
using NIH Image software.
2.6.StatisticalAnalysis. Dataarepresentedasmeans(s.e.m.).
Statistical analysis was performed using SigmaPlot software
v8.0 (SPSS Inc., Chicago, IL). One-way analysis of variance
or, where appropriate, repeated measures ANOVA, with a
Student Newman Keuls post hoc test were performed on




lines after 24hrs and 48hrs of incubation; whereas leptin’s
proliferative eﬀect on androgen-sensitive cells was much less
pronounced. As shown in Figures 1(a)–1(c),c e l ln u m b e r s
were dose-dependently (5–100ng/mL) increased at 24 and
48 hours after leptin treatment in DU145 and PC-3 cell lines
when compared to cell numbers in serum-free control cul-
tures. Maximal growth responses were observed after 48h at
a leptin concentration of 100ng/mL: 161.2±5.1% of control
in DU145 cells (P<0.001) and 182.7 ± 7.9% of control in
PC-3 cells (P<0.001). However, treatment of LNCaP cells
with leptin (100ng/mL) for up to 48 hours triggered only a
small eﬀect on cell proliferation (percent of control; 112.3 ±
6.1%; 100ng/mL leptin; 48hrs).
A common intracellular pathway that has been shown
to be recruited by leptin receptors is the mitogen-activated
protein kinase (MAPK) cascade [17, 23, 24]. To evaluate
if leptin’s mitogenic action in androgen-resistant prostate
cancer cells is linked to proliferative signaling through acti-
vation of the MAPK signaling pathway, DU145, PC-3, and
LNCaP cells were treated with leptin and phosphorylation
of p42/44 MAPK (ERK1/2), a downstream component of
MAPK pathway was measured by Western blotting using
phosphospeciﬁc antibodies. As would be expected from
proliferation assay data, leptin treatment evoked ERK phos-
phorylation in both androgen-resistant cell lines in a dose-
dependent manner (Figures 2(a) and 2(b)). In LNCaP cells,
however, leptin also evoked activation of ERK phosphoryla-
tion, but to a comparably lesser extent (data not shown).
To further investigate whether leptin-stimulated MAPK
activation is linked to cell proliferation in androgen-resistant
cells, a speciﬁc inhibitor was used to block this signaling
pathway. Leptin alone increased cell proliferation in both
androgen-resistant cell lines. However, pretreatment of cell
lines with the MEK inhibitor PD98059 (40µM) markedly
reduced cell proliferation in both cell lines (Figures 3(a) and
3(b)).
4. Discussion
The prevalence of obesity is increasing among the world
population [1]. The comorbidities associated with obesity
represent an enormous burden on health care systems [25].
It is, therefore, important to understand the relationships
between obesity and a number of diseases, including cancer,
and the mechanisms involved in their interaction. In a
prospectively studied cohort of 900,000 U.S. adults, Calle
et al. found that obese patients were more likely to die
from a number of cancers, including prostate cancer [26].
Further, some links between obesity and cancer has been also
strongly documented in diﬀerent cancer types, for example,
breast cancer and colonic cancer [27, 28]. However, studies
of obesity and prostate cancer are complicated by the fact
that obesity is associated not only with excess body fat,
but also with altered serum levels of numerous hormones,
including testosterone, estrogen, insulin, insulin-like growth
factor (IGF)-1, and leptin, all which have to some degree
been linked to prostate cancer [3]. For instance, mitogenic
actionsofleptinincertainorgansinbothnormalanddisease
states have been reported and increasing epidemiological
data in humans, as well as numerous in vitro investigation
and animal studies suggest a link between leptin and cancer
growth [17, 29]. The leptin receptor isoforms (ObRa and
ObRcthroughObRf)havebeenreportedinawidevarietyof
human and rodent tissues: heart, placenta, lung, liver, mus-
cle, kidney, pancreas, spleen, thymus, prostate, testes, ovary,
smallintestine,andcolon[30–32].In vitro,ithasbeenshown
that human prostate cancers express the leptin receptor and
leptin is able to stimulate growth of some human prostate
cancer cell lines [22, 33–37]. The present study was under-
taken to further investigate the eﬀect of leptin on growth
of prostate cancer cells as we have tested the hypothesis
whether the increase in prostate cancer growth by leptin
might be diﬀerent in androgen-resistant cells compared to
androgen-sensitive cells. Further, the potential involvement
of major mitogenic signal transduction pathways, such as
MAPK pathway was evaluated by measuring the activation
of its downstream component (ERK1/2) in these cell lines.
Tocharacterizethediﬀerenceinproliferativeeﬀectsofleptin,
three diﬀerent human prostate cancer cell lines were treated
with leptin. Leptin treatment for up to 48 hours increased
prostate cell proliferation in a dose-dependent manner in
androgen-resistant cells, with a maximal proliferative eﬀect
between concentrations of 50 and 100ng/mL (Figures 1(a)
and 1(b)). This is the range of concentration that has been
measured in serum of obese patients as it has been shown
that circulating serum leptin levels correlate with body
fat content and obese humans have as high as 100ng/mL
(average of 40ng/mL) serum leptin levels, whereas lean
individuals have 1–3ng/mL (average 4ng/mL) serum leptin
levels [15, 20].
However, while androgen-sensitive cells showed only a
slight proliferative response to leptin treatment, there was
strongerresponseinPC3cells,whencomparedtotheDU145
responses (Figures 1(a)–1(c)). The reason for the latter
ﬁnding might be that DU145 cells have been speculated to
have much moderate metastatic potential compared to PC3
cells which might have higher metastatic potential [38]. A
diﬀerence in response to leptin among the diﬀerent cell lines
from the same organ and/or diﬀerent organs has also seen in
other studies [17, 23, 29, 34, 39].
Mitogenic actions of leptin in certain organs in both
normal and disease have been reported [16, 38]. Again,
for prostate cancer cells, most studies reported mitogenic





























































































































Figure 1: Leptin increases cell proliferation in androgen-resistant prostate cancer cell lines ((a); PC-3, (b); DU145) in a dose-dependent
manner. Conversely, leptin’s proliferative eﬀect on androgen-sensitive cell line ((c); LNCaP) was much less pronounced. Cells were cultured
in serum-free media for 24 hours (white bars) or 48 hours (black bars) in the presence or absence of leptin (0–100ng/mL) and cell numbers
were determined by a colorimetric XTT assay. Assays were performed at least ﬁve times and samples were run in triplicate. The data (means
± SEM) are reported as a percentage of results in untreated controls and asterisks or pound signs denote values signiﬁcantly diﬀerent from
these cells at 24 and 48hrs, respectively, (∗ or #P<0.05; ∗∗ or ##P<0.01; ∗∗∗ or ###P<0.001 by ANOVA).
lines DU145 and PC-3 cells, while androgen-sensitive cell
line LNCaP cells were mostly unresponsive or not tested
[21, 22, 34]. As one of the few studies, Onuma et al. reported
on mitogenic actions of leptin in androgen-independent
cell lines PC3 and DU145, but not in androgen-dependent
cell line LNCaP-FGC [21]. However, it is noteworthy,
that in contrast to our study, they used very high supra-
physiologic concentrations for the cell treatments with leptin
(12.5µg/mL). Also, they used very long incubation time of 5
days, which was in clear contrast to our study [21]. However,
as the number of reported studies in the literature increases,
the problem of reporting conﬂicting results regarding the
proliferative and/or (anti-)apoptotic eﬀects of leptin on PCa
cells and the involved signaling mechanisms remains. As a
consequence, most studies vary widely in the dose range of
leptin, time-length of leptin treatment, and the models used
or the parameters tested and accordingly, also in the results
obtained on the eﬀects of leptin. For instance, Somasundar
et al. reported that in DU145 cells, proliferation was signif-
icantly increased by 4 and 40ng/mL after 72hrs of leptin
treatment, as measured by MTT assay [20]. In contrast to
our study, they performed their proliferation assays only at 2
time-points (24 and 72hrs) and using only 2 doses of leptin
(4 and 40ng/mL). Thus, some more pronounced eﬀects of
leptin in higher dose ranges (50–100ng/mL), as this also
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Figure 2: Leptin activates ERK1/2 isoforms of MAPK signaling pathway in a dose-dependent manner in androgen-resistant prostate cancer
cell lines (DU145 and PC-3). Three diﬀerent human prostate cancer cell lines were cultured in serum-free media for 24hrs followed by
exposure to recombinant human leptin for 1 hour. Cellular extracts were fractioned onto 12% SDS-Page and Western immunoblotting
performed with a rabbit polyclonal anti-phospho-p44/42 MAPK as described in Section 2. The ﬁndings are from a single experiment

















































































































Figure 3: Inhibitor of MAPK attenuates leptin-induced prostate cancer cell growth in androgen-resistant prostate cancer cell lines. Cells
((a); PC-3, (b); DU145) were cultured in serum-free media for 24 and 48 hours with or without leptin (100ng/mL). Before adding leptin,
cells were pretreated with the MEK inhibitor PD98059 (PD; 40µM). Cell number was determined by the colorimetric XTT assay. Assays
were performed at least ﬁve times and samples were run in triplicate. The data (means ± SEM) are reported as percentage of the untreated
control and asterisks denote values signiﬁcantly diﬀerent from vehicle-treated cells. (∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 by ANOVA).
been missed by their study. Interstingly, they also observed
ad i ﬀerent pattern of mitogenic action of leptin in PC-3
cells, as these had a maximum growth response to 4ng/mL
leptin at the 24hrs time period [20]. Further, Somasundar et
al. showed also an inhibition of serum-deprivation-induced
apoptosis by leptin in dose rage of 40ng/mL (24hrs) in
PC-3 and DU145 cells [20]. However, unlike our previously
published study, the found somewhat conﬂicting results for
low-dose leptin (4ng/mL), as this increased apoptosis in PC-
3cellsandinhibiteditinDU145cells[22].Asamatteroffact,
it seems that leptin eﬀects on apoptosis in prostate cancer
cells continue to be a subject for serious debate, as also some
very conﬂicting resultsare available now in the literature.For
instance, Samuel-Mendelsohn et al. reported very recently
their surprising ﬁnding that leptin exerted proapoptotic
eﬀects in four PCa cell lines (PC3, DU145, PC3/AR and
LNCaP),asassessedbyfourdiﬀerentparametersofapoptosis
[40]. In these studies, they induced apoptosis in the cells
using starvation medium for 48hrs. The proapoptotic
response to leptin in this study was rapid and sensitive, being
maximal already with 1ng/mL and 6hrs of exposure [40].
The proapoptotic eﬀect of leptin was maintained in all cell6 Journal of Oncology
lines for up to 24hrs, and then mostly reduced by 72hrs
[40]. As possible explanation for these conﬂicting results
concerning the apoptosis, in can be presumed the ability
of leptin to variously aﬀect the balance between pro- and
antiapoptotic signals, depending on the cell type, dose of
leptin treatment, and the pathophysiological and molecular
milieu active at a given point in time [20–22, 40]. Recent
studies show also that the ability of leptin to aﬀect cell
growth and apoptosis and androgen receptor expression in
various human prostate cancer cell lines is likely related
to the complexity of the eﬀects mediated by its full-length
receptor in activating diﬀerent intracellular signalling path-
ways [40]. Nevertheless, the exact mechanisms of these
varieties in leptins eﬀect are still unknown and because the
eﬀects of leptin can clearly vary between diﬀerent types of
cancer, diﬀerent cancer cells, or even at diﬀerent stages of
progression of a given cancer cell type, an important goal
to be achieved will be the development of targeted leptin
receptoragonistsandantagonistsaimedataspeciﬁcfunction
of leptin and/or a speciﬁc marker in a given cancer cell type.
However, the ultimate goal of such studies should be to
clarify whether the obesity-related hyperleptinemia is likely a
risk factor for occurrence of androgen-resistency in prostate
cancer. As pointed out by Ribeiro et al., this fact should
already be considered in current clinical hormonal therapy
for prostate cancer, which includes the use of antiandrogens,
and LHRH analogues [41]. The ultimate goal of this therapy
is the blockade of androgen production with subsequent
decrease in androgen serum levels. Considering the inverse
relationship between serum levels of cortisol, and other
steroids including androgens, a blockade of androgens will
be followed by an increase in leptin expression [42, 43].
Ribeiro et al. suggest that the unbalanced serum increase in
leptin and decrease in androgens may facilitate androgen-
independent cell growth, while downregulating androgen-
dependent cells [41]. However, more studies are needed to
clarify the clinical impact of this hypothesis.
Signal transduction pathways play an important role in
cancer cell proliferation, apoptosis, oncogenic transforma-
tion, and tumor progression, and these pathways involve
proteinkinasesatmultiplelevels[23,44].Therefore,Western
blot studies were conducted to evaluate the pathways related
to cell proliferation that are activated upon treatment with
leptin. In particular, the MAPK signaling pathway is known
to be important in cancer cell survival and growth. Thus,
the potential involvement of MAPK signal transduction
pathway in mediating the eﬀects of leptin in prostate cell
lines was examined by measuring the phosphorylation of its
downstream component ERK1/2. It could be demonstrated
that leptin induces ERK1/2 activation in conjunction with
increased cell proliferation in both cell lines (Figures 2(a)
and 2(b)). Although we did not observe this, Somasundar
et al. had reported in an earlier work that the activation of
diﬀerent components of signal-transduction pathways upon
treatment of cell lines with leptin might be depending on
cell type [20]. For instance, they observed that in DU145
prostate cancer cell line, leptin increased the PI3-K pathway
by activation of p-Akt in a dose-dependent manner (0–
80ng/mL) at the 4-h time point, whereas in the same cell
line, there was a weak p-ERK activity in response to leptin.
In the PC-3 prostate cancer cell line, p-ERK activity was
increased in the dose-dependent manner and time eﬀects
were observed to 4h [20]. Beside the fact that they did not
assessed leptin eﬀects in androgen-sensitive cell line, their
ﬁnding regarding p-ERK activity is somewhat diﬀerent than
our ﬁndings, as we observed strong activity of p-ERK in
the dose rage of 25–100ng/mL leptin treatment in both cell
lines (Figure 2). However, as already pointed out above, as
a possible explanation, we suspect that the diﬀerences in
results between our studies could be due to diﬀerences in
the amount of time treated with leptin, as Somasundar et al.
used2–4hoursoftreatment,whileweusedonlyoneuniform
time point of 1 hour for leptin treatment for our Western
blot studies. Further, Samuel-Mendelsohn et al. reported in
a very recent paper that exposure of native PC3, DU145, and
LNCaP cells to leptin caused weak to modest, but statistically
signiﬁcant,increaseinthephosphorylationofsomesignaling
pathways engaged in apoptosis and cell proliferation, such as
JAK2, STAT3, ERK1/2, and also PI3K-Akt [40]. However, it
should be noted that compared to our studies, also in their
study, diﬀerent treatment doses of leptin (0.1 to 10ng/mL)
and very short time of exposure (7 minutes) were present. As
a matter of fact, in contrast to all other studies published so
far,inordertoincreasethesignalsinducedbyleptinexposure
in the studied cell lines, they transiently overexpressed the
LRb and JAK2 genes in the PCa cells by cotransfection with
their cDNAs [20]. However, it is not uncommon to ﬁnd
diﬀerencesinsignaltransductionpathwayswithdiﬀerentcell
lines owing to their genetic deletions and/or mutations [20].
Nevertheless, it is important to notice that in our studies
a speciﬁc biochemical blocker of the MAPK-pathway, the
MEK inhibitor PD98059 (40µM), was able to abolish the
mitogenic eﬀects of leptin in both cell lines, indicating an
involvement of this pathway in proliferation in both cell lines
(Figure 3).
In conclusion, the present study showed that the eﬀect of
leptinongrowthofprostatecancercellsisdiﬀerentaccording
to the androgen sensitivity of the evaluated cells. It could be
further conﬁrmed that major mitogenic signal transduction
pathways, such as MAPK pathway are involved in leptin
exerting its mitogenic eﬀects in these cell lines. Further
investigation is strongly encouraged in order to investigate
whether the ability of leptin to stimulate proliferation of
androgen-resistant prostate cancer cells might represent a
novel diagnostic/prognostic factor by serial measurements of
the serum leptin levels during the course of a certain therapy.
Additionally, activation of mitogenic signal transduction
pathways by leptin could potentially serve as a target for
future therapies of advanced stages of PCa.
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